表紙
市場調查報告書

肝炎治療藥的開發平台分析

Hepatitis Drug Development Pipeline Review, 2018

出版商 GlobalData 商品編碼 537171
出版日期 內容資訊 英文 133 Pages
訂單完成後即時交付
價格
肝炎治療藥的開發平台分析 Hepatitis Drug Development Pipeline Review, 2018
出版日期: 2018年06月29日內容資訊: 英文 133 Pages
簡介

本報告提供各種肝炎 (A型、B型、C型、D型肝炎)的治療藥臨床實驗、開發趨勢相關分析,疾病概要,及到目前為止的治療藥的開發、上市情形,現在臨床實驗中/審查中的的主要開發中產品一覽,暫停中、已中止的計劃的概要,今後臨床實驗的方向性和實現預測等的相關調查。

分析概論

摘要整理

目錄、圖表一覽

簡介

  • 分析範圍
  • A型肝炎:概要
  • B型肝炎:概要
  • C型肝炎:概要
  • D型肝炎:概要

治療藥的開發

  • A型肝炎
  • B型肝炎
  • C型肝炎
  • D型肝炎

治療藥的評估

治療藥開發的參與企業

現在暫停中的計劃

開發中止的計劃

產品開發里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GBIHC039IDB

Summary:

Hepatitis refers to inflammation of the liver and is most commonly caused by viral infections. Hepatitis A and E are typically caused by ingestion of contaminated food or water. Symptoms of hepatitis A infection include fatigue, nausea and vomiting, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes.

Risk factors include a weakened immune system and use of injected or non-injected illicit drugs. Symptoms of hepatitis E include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite and pain in the abdomen.

Hepatitis B and hepatitis D infection typically occur as a result of contact with infected body fluids. Transmission of hepatitis B can occur via sexual contact, injection drug use or transfusions of contaminated blood and blood products. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes, dark urine, extreme fatigue, nausea, vomiting and abdominal pain.

Hepatitis D infection only occurs in persons previously infected with hepatitis B, as the hepatitis D virus can only replicate in the presence of hepatitis B. The co-infection of hepatitis B and hepatitis D is associated with greater disease severity than hepatitis B infection alone.

Companies operating in this pipeline space include Cadila Healthcare and Chongqing Zhifei Biological Products.

This report "Hepatitis Drug Development Pipeline Review, 2018" provides an overview of the pipeline landscape for hepatitis infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hepatitis A, hepatitis B, hepatitis D and hepatitis E, and features dormant and discontinued products.

Scope:

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy:

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Hepatitis Report Coverage
  • 2.2. Hepatitis A - Overview
  • 2.3. Hepatitis B - Overview
  • 2.4. Hepatitis D - Overview
  • 2.5. Hepatitis E - Overview

3. Therapeutics Development

  • 3.1. Hepatitis A
  • 3.2. Hepatitis B
  • 3.3. Hepatitis D
  • 3.4. Hepatitis E

4. Therapeutics Assessment

  • 4.1. Hepatitis A
  • 4.2. Hepatitis B
  • 4.3. Hepatitis D
  • 4.4. Hepatitis E

5. Companies Involved in Therapeutics Development

  • 5.1. Hepatitis A
  • 5.2. Hepatitis B
  • 5.3. Hepatitis D
  • 5.4. Hepatitis E

6. Dormant Projects

  • 6.1. Hepatitis A
  • 6.2. Hepatitis B
  • 6.3. Hepatitis D
  • 6.4. Hepatitis E

7. Discontinued Products

  • 7.1. Hepatitis B

8. Product Development Milestones

  • 8.1. Hepatitis B
  • 8.2. Hepatitis D
  • 8.3. Hepatitis E

9. Appendix

  • 9.1. Methodology
  • 9.2. Coverage
  • 9.3. Secondary Research
  • 9.4. Primary Research
  • 9.5. Expert Panel Validation
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Hepatitis A
  • Table 2: Number of Products under Development by Companies, Hepatitis A
  • Table 3: Number of Products under Development by Universities/Institutes, Hepatitis A
  • Table 4: Products under Development by Companies, Hepatitis A
  • Table 5: Products under Development by Universities/Institutes, Hepatitis A
  • Table 6: Number of Products under Development for Hepatitis B
  • Table 7: Number of Products under Development by Companies, Hepatitis B
  • Table 8: Number of Products under Development by Universities/Institutes, Hepatitis B
  • Table 9: Products under Development by Companies, Hepatitis B
  • Table 10: Products under Development by Universities/Institutes, Hepatitis B
  • Table 11: Number of Products under Development for Hepatitis D
  • Table 12: Number of Products under Development by Companies, Hepatitis D
  • Table 13: Number of Products under Development by Universities/Institutes, Hepatitis D
  • Table 14: Products under Development by Companies, Hepatitis D
  • Table 15: Products under Development by Universities/Institutes, Hepatitis D
  • Table 16: Number of Products under Development for Hepatitis E
  • Table 17: Number of Products under Development by Companies, Hepatitis E
  • Table 18: Number of Products under Development by Universities/Institutes, Hepatitis E
  • Table 19: Products under Development by Companies, Hepatitis E
  • Table 20: Products under Development by Universities/Institutes, Hepatitis E
  • Table 21: Number of Products by Stage and Route of Administration, Hepatitis A
  • Table 22: Number of Products by Stage and Molecule Type, Hepatitis A
  • Table 23: Number of Products by Stage and Target, Hepatitis B
  • Table 24: Number of Products by Stage and Mechanism of Action, Hepatitis B
  • Table 25: Number of Products by Stage and Route of Administration, Hepatitis B
  • Table 26: Number of Products by Stage and Molecule Type, Hepatitis B
  • Table 27: Number of Products by Stage and Target, Hepatitis D
  • Table 28: Number of Products by Stage and Mechanism of Action, Hepatitis D
  • Table 29: Number of Products by Stage and Route of Administration, Hepatitis D
  • Table 30: Number of Products by Stage and Molecule Type, Hepatitis D
  • Table 31: Number of Products by Stage and Target, Hepatitis E
  • Table 32: Number of Products by Stage and Mechanism of Action, Hepatitis E
  • Table 33: Number of Products by Stage and Route of Administration, Hepatitis E
  • Table 34: Number of Products by Stage and Molecule Type, Hepatitis E
  • Table 35: Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co Ltd
  • Table 36: Hepatitis A - Pipeline by Cadila Healthcare Ltd
  • Table 37: Hepatitis A - Pipeline by China National Pharmaceutical Group Corp
  • Table 38: Hepatitis A - Pipeline by Indian Immunologicals Ltd
  • Table 39: Hepatitis A - Pipeline by Sinovac Biotech Ltd
  • Table 40: Hepatitis B - Pipeline by Abivax SA
  • Table 41: Hepatitis B - Pipeline by AiCuris GmbH & Co KG
  • Table 42: Hepatitis B - Pipeline by AIMM Therapeutics BV
  • Table 43: Hepatitis B - Pipeline by Akshaya Bio Inc
  • Table 44: Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc
  • Table 45: Hepatitis B - Pipeline by Altimmune Inc
  • Table 46: Hepatitis B - Pipeline by Altravax Inc
  • Table 47: Hepatitis B - Pipeline by Amarna Therapeutics BV
  • Table 48: Hepatitis B - Pipeline by Arbutus Biopharma Corp
  • Table 49: Hepatitis B - Pipeline by Arcturus Therapeutics Ltd
  • Table 50: Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc
  • Table 51: Hepatitis B - Pipeline by Ascentage Pharma Group Corp Ltd
  • Table 52: Hepatitis B - Pipeline by Assembly Biosciences Inc
  • Table 53: Hepatitis B - Pipeline by Aucta Pharmaceuticals LLC
  • Table 54: Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd
  • Table 55: Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd
  • Table 56: Hepatitis B - Pipeline by Benitec Biopharma Ltd
  • Table 57: Hepatitis B - Pipeline by Biological E Ltd
  • Table 58: Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc
  • Table 59: Hepatitis B - Pipeline by Biotron Ltd
  • Table 60: Hepatitis B - Pipeline by Bolder Biotechnology Inc

List of Figures

  • Figure 1: Number of Products under Development for Hepatitis A
  • Figure 2: Number of Products under Development by Companies, Hepatitis A
  • Figure 3: Number of Products under Development for Hepatitis B
  • Figure 4: Number of Products under Development by Companies, Hepatitis B
  • Figure 5: Number of Products under Development by Universities/Institutes, Hepatitis B
  • Figure 6: Number of Products under Development for Hepatitis D
  • Figure 7: Number of Products under Development by Companies, Hepatitis D
  • Figure 8: Number of Products under Development for Hepatitis E
  • Figure 9: Number of Products under Development by Companies, Hepatitis E
  • Figure 10: Number of Products by Stage and Routes of Administration, Hepatitis A
  • Figure 11: Number of Products by Molecule Types, Hepatitis A
  • Figure 12: Number of Products by Stage and Molecule Types, Hepatitis A
  • Figure 13: Number of Products by Top 10 Targets, Hepatitis B
  • Figure 14: Number of Products by Stage and Top 10 Targets, Hepatitis B
  • Figure 15: Number of Products by Top 10 Mechanism of Actions, Hepatitis B
  • Figure 16: Number of Products by Stage and Top 10 Mechanism of Actions, Hepatitis B
  • Figure 17: Number of Products by Routes of Administration, Hepatitis B
  • Figure 18: Number of Products by Stage and Routes of Administration, Hepatitis B
  • Figure 19: Number of Products by Top 10 Molecule Types, Hepatitis B
  • Figure 20: Number of Products by Stage and Top 10 Molecule Types, Hepatitis B
  • Figure 21: Number of Products by argets, Hepatitis D
  • Figure 22: Number of Products by Stage and Targets, Hepatitis D
  • Figure 23: Number of Products by Mechanism of Actions, Hepatitis D
  • Figure 24: Number of Products by Stage and Mechanism of Actions, Hepatitis D
  • Figure 25: Number of Products by Routes of Administration, Hepatitis D
  • Figure 26: Number of Products by Stage and Routes of Administration, Hepatitis D
  • Figure 27: Number of Products by Molecule Types, Hepatitis D
  • Figure 28: Number of Products by Stage and Molecule Types, Hepatitis D
  • Figure 29: Number of Products by Molecule Types, Hepatitis E
  • Figure 30: Number of Products by Stage and Molecule Types, Hepatitis E